Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company will immediately begin to execute on the integration of these two leading businesses, to converge human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company.
Company profile
Ticker
VYNT
Exchange
Website
CEO
John Roberts
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CANCER GENETICS INC, CANCER GENETICS, INC
SEC CIK
Corporate docs
Subsidiaries
StemoniX, Inc. • vivoPharm Pty, Ltd. ...
IRS number
43462475
VYNT stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
15 Aug 23
PRE 14A
Preliminary proxy
31 Jul 23
15-12G
Securities registration termination
15 May 23
8-K
Departure of Directors or Certain Officers
10 May 23
25
Voluntary exchange delisting
4 May 23
8-K
Vyant Bio Announces Voluntary Nasdaq Delisting and SEC Deregistration
24 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
EFFECT
Notice of effectiveness
28 Mar 23
EFFECT
Notice of effectiveness
28 Mar 23
EFFECT
Notice of effectiveness
28 Mar 23
Transcripts
VYNT
Earnings call transcript
2022 Q3
17 Nov 22
VYNT
Earnings call transcript
2022 Q2
23 Aug 22
VYNT
Earnings call transcript
2022 Q1
17 May 22
VYNT
Earnings call transcript
2021 Q4
30 Mar 22
VYNT
Earnings call transcript
2021 Q3
15 Nov 21
VYNT
Earnings call transcript
2021 Q2
17 Aug 21
VYNT
Earnings call transcript
2018 Q2
14 Aug 18
VYNT
Earnings call transcript
2018 Q1
15 May 18
VYNT
Earnings call transcript
2017 Q4
2 Apr 18
VYNT
Earnings call transcript
2017 Q3
9 Nov 17
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.04 mm | 10.04 mm | 10.04 mm | 10.04 mm | 10.04 mm | 10.04 mm |
Cash burn (monthly) | (no burn) | 880.58 k | 1.17 mm | 1.33 mm | 1.10 mm | 1.14 mm |
Cash used (since last report) | n/a | 13.14 mm | 17.39 mm | 19.79 mm | 16.37 mm | 17.01 mm |
Cash remaining | n/a | -3.10 mm | -7.35 mm | -9.75 mm | -6.33 mm | -6.97 mm |
Runway (months of cash) | n/a | -3.5 | -6.3 | -7.4 | -5.8 | -6.1 |
Institutional ownership, Q1 2023
18.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 109.10 mm |
Total shares | 1.15 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lind Global Macro Fund | 689.66 k | $931.00 k |
Bigger Capital Fund L P | 244.83 k | $331.00 k |
Vanguard | 47.26 k | $27.41 mm |
Geode Capital Management | 38.82 k | $22.52 mm |
Mayo Clinic | 27.74 k | $16.09 mm |
BLK Blackrock | 26.56 k | $15.40 mm |
Susquehanna International | 20.00 k | $11.60 mm |
STT State Street | 15.04 k | $8.72 mm |
Renaissance Technologies | 13.82 k | $8.00 k |
VIRT Virtu Financial | 12.52 k | $7.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jan 23 | Fletcher R John | Common Stock, $0.0001 par value | Grant | Acquire A | No | No | 0 | 4,368 | 0.00 | 23,895 |
17 Jan 23 | Horobin Joanna | Common Stock, $0.0001 par value | Grant | Acquire A | No | No | 0 | 7,526 | 0.00 | 23,123 |
17 Jan 23 | Paul R. Hansen | Common Stock, $0.0001 par value | Grant | Acquire A | No | No | 0 | 4,032 | 0.00 | 152,995 |
17 Jan 23 | Geoffrey E. Harris | Common Stock, $0.0001 par value | Grant | Acquire A | No | No | 0 | 5,712 | 0.00 | 19,761 |
18 Nov 22 | Geoffrey E. Harris | Common Stock, $0.0001 par value | Sell | Dispose S | No | No | 1.334 | 666 | 888.44 | 14,019 |
18 Nov 22 | Geoffrey E. Harris | Common Stock, $0.0001 par value | Sell | Dispose S | No | No | 1.3401 | 99 | 132.67 | 14,685 |